<DOC>
	<DOCNO>NCT01033019</DOCNO>
	<brief_summary>This double-blinded , randomize , vehicle-controlled study sporadic superficial BCC ( sBCC ) nodular BCC ( nBCC ) patient consist 21-day screening period , treatment period 6 week ( topical 0.75 % LDE225 cream application b.i.d ) end post treatment biopsy , safety visit one week final study drug administration ( Day 50 ) , visit Day 83 excision treat BCC , end study evaluation ( Day 90 ) .</brief_summary>
	<brief_title>To Evaluate Safety , Local Tolerability , PK PD LDE225 Sporadic Superficial Nodular Skin Basal Cell Carcinomas ( sBCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Patients one histologically confirm superficial nodular basal cell carcinoma ( 820 mm ) eligible surgical excision select body area ( scalp , arm , frontal trunk , posterior trunk , upper leg ) Previous treatment sBCC select treatment . Any systemic treatment know affect BCCs esp . cytostatic treatment , retinoids photodynamic treatment . Darkskinned person whose skin color prevents readily assessment skin reaction Other protocol define Incl./Excl . criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Basal cell carcinoma ,</keyword>
	<keyword>sporadic ,</keyword>
	<keyword>superficial nodular ,</keyword>
	<keyword>skin</keyword>
</DOC>